Qifu Yixin Formula Improves Heart Failure by Enhancing β-Arrestin2 Mediated the SUMOylation of SERCA2a
Drug Design, Development and Therapy · 2024-03 · Volume 18 · 781-799
DOI: 10.2147/dddt.s446324 ↗Kurz gefasst
Fachartikel in der Zeitschrift Drug Design, Development and Therapy, 2024-03. Verfasst von Xinting Wang und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology, Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai, 200021, People's Republic of…. Hauptthemen laut MEDLINE: Sumoylation, Heart Failure. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).
Themen: Herzinsuffizienz
Abstract (Originalsprache)
Purpose
This study aimed to elucidate the protective mechanism of Traditional Chinese Medicine (TCM) Qifu Yixin formula (QFYXF) to improve heart failure (HF) by promoting β-arrestin2 (β-arr2)-mediated SERCA2a SUMOylation. Materials and Methods: The transverse aortic constriction (TAC)-induced HF mice were treated with QFYXF or carvedilol for 8 weeks. β-arr2-KO mice and their littermate wild-type (WT) mice were used as controls. Neonatal rat cardiomyocytes (NRCMs) were used in vitro. Cardiac function was evaluated by echocardiography and serum NT-proBNP. Myocardial hypertrophy and myocardial fibrosis were assessed by histological staining. β-arr2, SERCA2a, SUMO1, PLB and p-PLB expressions were detected by Western blotting, immunofluorescence and immunohistochemistry. SERCA2a SUMOylation was detected by Co-IP. The molecular docking method was used to predict the binding ability of the main active components of QFYXF to β-arr2, SERCA2a, and SUMO1, and the binding degree of SERCA2a to SUMO1 protein.
Results
The HF model was constructed 8 weeks after TAC. QFYXF ameliorated cardiac function, inhibiting myocardial hypertrophy and fibrosis. QFYXF promoted SERCA2a expression and SERCA2a SUMOylation. Further investigation showed that QFYXF promoted β-arr2 expression, whereas Barbadin (β-arr2 inhibitor) or β-arr2-KO reduced SERCA2a SUMOylation and attenuated the protective effect of QFYXF improved HF. Molecular docking showed that the main active components of QFYXF had good binding activities with β-arr2, SERCA2a, and SUMO1, and SERCA2a had a high binding degree with SUMO1 protein.
Conclusion
QFYXF improves HF by promoting β-arr2 mediated SERCA2a SUMOylation and increasing SERCA2a expression.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Cardiology, Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai, 200021, People's Republic of China.
- Department of Cardiology, Seventh People's Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai, 200137, People's Republic of China.
ORCID-Profile: Xinting Wang, Yinqin Hu
Zitieren
APA
Wang, X., Yang, J., Lu, C., Hu, Y., Xu, Z., Wan, Q., Zhang, M., Shi, T., Liu, Z., & Liu, Y. (2024). Qifu Yixin Formula Improves Heart Failure by Enhancing β-Arrestin2 Mediated the SUMOylation of SERCA2a. Drug Design, Development and Therapy, Volume 18, 781-799. https://doi.org/10.2147/dddt.s446324
Vancouver
Wang X, Yang J, Lu C, Hu Y, Xu Z, Wan Q, et al. Qifu Yixin Formula Improves Heart Failure by Enhancing β-Arrestin2 Mediated the SUMOylation of SERCA2a. Drug Design, Development and Therapy. 2024;Volume 18:781-799. doi:10.2147/dddt.s446324
BibTeX
@article{Wang2024,
author = {Wang, Xinting and Yang, Jiahui and Lu, Cheng and Hu, Yinqin and Xu, Zhaohui and Wan, Qiqi and Zhang, Meng and Shi, Tianyun and Liu, Zhirui and Liu, Yongming},
title = {Qifu Yixin Formula Improves Heart Failure by Enhancing β-Arrestin2 Mediated the SUMOylation of SERCA2a},
journal = {Drug Design, Development and Therapy},
year = {2024},
volume = {Volume 18},
pages = {781--799},
doi = {10.2147/dddt.s446324}
}
EUVIMED